BioSpace News Archive

Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, reported that an independent study conducted in Madrid, Spain has confirmed the high performance characteristics of the Company’s MosaiQ COVID-19 Antibody Microarray.

Ensuring supplies and medications are where they are needed, when they are needed has never been simple, even before COVID-19.

Transitional Pass-Through Payment Reimburses Hospital Outpatient and Ambulatory Surgical Centers for Incremental Cost of AUGMENT in Hindfoot and Ankle Fusion Procedures

Baudax Bio, Inc., a pharmaceutical company focused on therapeutics for acute care settings, announced that it has entered into a Pharmacy Supplier Agreement with Vizient, Inc. effective as of July 1, 2020, to offer ANJESO injection, a non-opioid option for managing moderate to severe pain.

New PST 500 Precision Surgical Table and Yellofins Apex™ Stirrups provide caregivers with advanced OR technologies

Pioneering Microbiome Company Demonstrates Significant Clinical Results from Use of Microbiome-Based Synbiotic in Patients with Type 2 Diabetes

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the development and advancement of immunology based therapies for prevalent inflammatory conditions, today announced the publication “Insights into pediatric multi-system inflammatory syndrome and COVID-19.”

Cytocom, Inc. , a private clinical-stage biopharmaceutical company developing novel immune modulating therapies targeting caner, autoimmune, inflammatory, and infectious diseases based on proprietary plat

Roflumilast foam potential “Best in Class” topical PDE4 inhibitor in foam formulation Scalp psoriasis affects more than 2.5 million U.S. patients Phase 2b topline data anticipated fourth quarter

Belite Bio, a clinical-stage biotech company, today announced positive results from two Phase 1 clinical trials in the United States and Australia for LBS-008, a First-in-Class oral small molecule Retinol Binding Protein 4 (RBP4) specific antagonist aimed to treat atrophic Age-related Macular Degeneration (Dry AMD) and Stargardt diseas